120131-72-8

Basic information

• Product Name: 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE
• Synonyms: 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE
• CAS NO: 120131-72-8
• Molecular Formula: C₁₄H₂₉N₃O₄
• Molecular Weight: 303.4
• Mol File: 120131-72-8.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE(120131-72-8)
• EPA Substance Registry System: 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE(120131-72-8)

Safety Data

• Hazardous Substances Data: 120131-72-8(Hazardous Substances Data)

Usage

Description

1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE is a PEG (Polyethylene Glycol) derivative that features an amino group with two Boc-protected amino groups. 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE is known for its reactivity with carboxylic acids, activated NHS esters, and carbonyls such as ketones and aldehydes. The Boc groups present in the molecule can be deprotected under mild acidic conditions, resulting in the formation of a free amine. It is a white powder in its chemical form.

Uses

Used in Pharmaceutical Industry:
1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE is used as a building block for the synthesis of various pharmaceutical compounds due to its reactivity with different functional groups. The Boc protection allows for selective deprotection, enabling the creation of complex molecular structures with controlled functionalization.
Used in Chemical Synthesis:
In the field of chemical synthesis, 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE serves as an intermediate for the production of various organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of specialty chemicals, including those with potential applications in materials science, agrochemicals, and other industries.
Used in Bioconjugation:
1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE is used as a bioconjugation agent for the attachment of biomolecules, such as proteins, peptides, and nucleic acids, to other molecules or surfaces. The Boc-protected amino groups facilitate the formation of stable covalent bonds, making it an ideal candidate for the development of bioconjugates with specific properties and functions.
Used in Drug Delivery Systems:
In the development of drug delivery systems, 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE can be utilized as a component in the design of targeted drug carriers. Its reactivity and Boc protection allow for the attachment of therapeutic agents and targeting moieties, enabling the creation of drug conjugates with enhanced specificity and efficacy.
Overall, 1,4-BIS-BOC-1,4,7-TRIAZAHEPTANE is a versatile PEG derivative with a wide range of applications in various industries, including pharmaceuticals, chemical synthesis, bioconjugation, and drug delivery systems. Its unique structure and reactivity make it a valuable asset in the development of innovative solutions and products.

Upstream product

• 263355-32-4 (2-tert-butoxycarbonylamino-ethyl)-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-carbamic acid tert-butyl ester 
• 647033-92-9 (2-tert-BOCamino-ethyl)-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 200283-08-5 (2-tert-butoxycarbonylaminoethyl)-(2-hydroxyethyl)carbamic acid tert-butyl ester 
• 187745-73-9 3-{tert-butoxycarbonyl-[2-(tert-butoxycarbonylamino)ethyl]amino}propionamide 
• 111-40-0 3-azapentane-1,5-diamine 

Downstream Products

• 1287220-08-9 methyl 4-(4-(2-(tert-butoxycarbonyl(2-(tert-butoxycarbonylamino)ethyl)amino)ethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1426097-16-6 (2-tert-butoxycarbonylaminoethyl)-{2-[2-(2-{[5-(2,6-dichlorophenyl)[1,2,4]triazin-3-ylamino]methyl}benzothiazol-5-yloxy)acetylamino]ethyl}carbamic acid tert-butyl ester 
• 1489230-64-9 C₃₁H₃₆BrN₅O₉ 
• 1429313-57-4 C₃₅H₅₄N₆O₇Si 
• 1429313-58-5 C₁₉H₂₄N₆O₃ 

Relevant articles and documents

Polycationic β-cyclodextrin "click clusters": Monodisperse and versatile scaffolds for nucleic acid delivery

Herein, a novel series of multivalent polycationic β-cyclodextrin "click clusters" with discrete molecular weight have been synthesized, characterized, and examined as therapeutic pDNA carriers. The materials were creatively designed based on a β-cyclodextrin core to impart a biocompatible multivalent architecture and oligoethyleneamine arms to facilitate pDNA binding, encapsulation, and cellular uptake. An acetylated-per-azido- β-cyclodextrin (4) was reacted with series of alkyne dendrons (7a-e) (containing one to five ethyleneamine units) using copper-catalyzed 1,3-dipolar cycloaddition, to form a series of click clusters (9a-e) bearing 1,2,3-triazole linkers. Gel electrophoresis experiments, dynamic light scattering, and transmission electron microscopy revealed that the macromolecules bind and compact pDNA into spherical nanoparticles in the size range of 80-130 nm. The polycations protect pDNA against nuclease degradation, where structures 9c, 9d, and 9e did not allow pDNA degradation in the presence of serum for up to 48 h. The cellular uptake profiles were evaluated in Opti-MEM and demonstrate that all the click clusters efficiently deliver Cy5-labeled pDNA into HeLa and H9c2 (2-1) cells, and compounds 9d and 9e yielded efficacy similar to that of the positive controls, Jet-PEI and Superfect. Furthermore, the luciferase gene delivery experiments revealed that the level of reporter gene expression increased with an increase in oligoethyleneamine number within the cluster arms. The cytotoxicity profiles of these materials were evaluated by protein, MTT, and LDH assays, which demonstrate that all the click clusters remain nontoxic within the expected dosage range while the positive controls, Jet PEI and Superfect, were highly cytotoxic. In particular, 9d and 9e were the most effective and promising polycationic vehicles to be further optimized for future systemic delivery experiments.

Substituted 9-aminoacridine-4-carboxamides tethered to platinum(II)diamine complexes: Chemistry, cytotoxicity and DNA sequence selectivity

Three platinum complexes in which substituted (7-OMe, 9-NH2; 7-F, 9-NH2; and 7-H, 9-NH(CH2)2OH) 9-aminoacridine-4-carboxamides were tethered to a platinum(II)diamine moiety were synthesised and characterised at the chemical and biological level. These variants showed a decrease in cytotoxicity, as measured by IC50 values in HeLa cells, when compared with the parent 7-H, 9-NH2 compound. The 7-F and 9-NH(CH2)2OH substituents gave rise to a small decrease in cytotoxicity, and the 7-OMe substituent resulted in a larger decrease in cytotoxicity. Their binding to purified pUC19 plasmid DNA was investigated and it was found that the addition of 7-F, 9-NH(CH2)2OH and especially the 7-OMe substituents, resulted in reduced DNA binding. This correlated well with the IC50 cytotoxicity values. However, the DNA sequence selectivity was unaffected by the addition of these moieties.

A Single Methylene Group in Oligoalkylamine-Based Cationic Polymers and Lipids Promotes Enhanced mRNA Delivery

The development of chemically modified mRNA holds great promise as a new class of biologic therapeutics. However, the intracellular delivery and endosomal escape of mRNA encapsulated in nanoparticles has not been systematically investigated. Here, we synthesized a diverse set of cationic polymers and lipids from a series of oligoalkylamines and subsequently characterized their mRNA delivery capability. Notably, a structure with an alternating alkyl chain length between amines showed the highest transfection efficiency, which was linked to a high buffering capacity in a narrow range of pH 6.2 to 6.5. Variation in only one methylene group resulted in enhanced mRNA delivery to both the murine liver as well as porcine lungs after systemic or aerosol administration, respectively. These findings reveal a novel fundamental structure–activity relationship for the delivery of mRNA that is independent of the class of mRNA carrier and define a promising new path of exploration in the field of mRNA therapeutics.

CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS

The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.